26th IFPMA assembly panel discussion II
Geneva, October 31, 2012
Panel II: “Creative Innovation: Addressing Key Research Gaps”
Ama de-Graft Aikins, Visiting Fellow, London School of Economics, Health
Francis Gurry, Director General, World Intellectual Property Organization
Trevor Mundel, President, Global Health Program, Gates Foundation
Dhaval D Patel, Head, Novartis Institutes for BioMedical Research Europe, Novartis
Bernard Pécoul, Executive Director, Drugs for Neglected Diseases Initiative
Ulf Wiinberg, President and CEO, Lundbeck
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.
Learn more
Related news and resources
WHO Intergovernmental Negotiating Body (INB) intersessional briefing on the “Transfer of technology and know-how”
On 20 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 7: Access to technology: promoting sustainable and equitably distributed production and transfer of technology and know-how” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).
Read moreStatement to the IHR Review Committee on amendments to the International Health Regulations
IFPMA encourages the consistent coordination of the INB and IHR processes to ensure a non-duplicative, fit-for-purpose outcome for all.
Read moreImpact of a waiver of intellectual property rights for COVID-19 therapeutics
As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.
Read more